E2 ModerateModerate confidencePEM unclearCross-SectionalPeer-reviewedMachine draft
High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome.
von Mikecz, A, Konstantinov, K, Buchwald, D S et al. · Arthritis and rheumatism · 1997 · DOI
Quick Summary
Researchers tested blood samples from 60 ME/CFS patients and found that 83% had unusual antibodies (immune proteins) attacking their own cells—specifically targeting proteins that form the structural framework inside and around cell nuclei. These antibodies were rarely seen in healthy people (only 17%), suggesting this autoimmune pattern might be unique to ME/CFS and could potentially help doctors identify the disease.
Why It Matters
This study identifies a distinctive immune signature in ME/CFS that differs markedly from typical autoimmune diseases, potentially providing a biological marker for diagnosis. Understanding these autoantibody patterns may help validate ME/CFS as a distinct pathophysiological entity and guide future diagnostic and therapeutic strategies.
Observed Findings
- 68% of CFS patients had antinuclear antibodies with varied subcellular localization patterns
- 47% of CFS patients had anticytoplasmic antibodies, predominantly targeting intermediate filaments
- 83% of CFS patients overall had antibodies to insoluble cellular antigens (lamin B1, vimentin, SC-35 cofactors)
- 17% of control patients without CFS had similar antibodies to insoluble antigens
- Identified antigens included lamin B1, vimentin, and nuclear envelope/splicing factor proteins
Inferred Conclusions
- The high frequency and specific pattern of autoantibodies to insoluble cellular antigens in CFS patients represents a unique humoral immune feature
- This autoantibody profile may be useful for distinguishing CFS from other rheumatic autoimmune diseases
- The targeting of insoluble cellular structural components (nuclear lamins, intermediate filaments) suggests a distinctive pathogenic immune mechanism in CFS
Remaining Questions
- Are these autoantibodies present in all ME/CFS patients or only in a subpopulation, and do they correlate with disease severity or symptoms?
- Do these antibodies persist over time or fluctuate with disease activity?
What This Study Does Not Prove
This study does not establish whether these autoantibodies cause ME/CFS symptoms or are merely a consequence of the disease. It also does not prove these antibodies are present in all ME/CFS patients or that they persist over time, nor does it demonstrate whether they have prognostic or therapeutic implications.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Weak Case DefinitionNo ControlsExploratory Only
Metadata
- DOI
- 10.1002/art.1780400215
- PMID
- 9041942
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →